Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Medtronic Canada, Perkinelmer.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accuhealth, Applied DNA Sciences, Bendit Technologies, Biocartis Group, Bone Therapeutics, Catalent Pharma Solutions, Closedloop.ai, DNAfit Life Sciences, Exact Sciences, Fitbit, Genomic Health, Health Catalyst, Livongo Health, Mammoth Biosciences, Mayo Clinic, Myapps, Natera, Optomec, Oxsed, Prenetics, Ping An, Premier Medical Laboratory Services, Progressive Care, Sanara Medical, Teladoc, Telli Health, Vocalis, Zerigo.
Keeping you up to date on recent developments in neurology, including: Software developed to objectively calculate white matter hyperintensities; CSF biomarkers point to underlying cause of neural damage in COVID-19; Scientists discover how cryptochrome mutation leads to sleep disorder; Physical labor significantly increases the risk of dementia.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Avrobio, Biocryst, Biogen, Cerecin, Equillium, Nexus, Novartis, Novo Nordisk, Regeneron, União Química, Trevena.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ADC Therapeutics, Genmab, Genprex, Havn, Innovation Pharmaceuticals, Janssen, Novartis, Oscine, OSE Immunotherapeutics, Protagonist, Sana.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Axovant, Bellicum, Biolinerx, Cerevel, Lilly.
DUBLIN – The global product development pipeline for COVID-19 is now twice as big as for any particular cancer indication, a major disease like Alzheimer’s or any other infectious disease indication.
TORONTO – Whether it’s President Trump obtaining the drug Regeneron or COVID-19 test kits fast tracked in the U.S. and Canada, this has been the year of temporary emergency approvals for drugs and medical devices. What is sometimes overlooked are permanent programs like Canada’s Special Access Program and the U.S.’s Expanded Access Program, designed to provide therapeutics to patients who have exhausted every avenue for a cure or relief from a devastating disease.
If a new federal rule withstands politics and potential court challenges, U.S. health care prices may finally be freed from their historic black box. The Centers for Medicare & Medicaid Services, along with the Departments of Labor and the Treasury, issued the Transparency in Coverage final rule Oct. 29 requiring most private health plans to disclose pricing and cost-sharing information so Americans will know in advance how much they will have to pay for prescription drugs, medical devices and other health care products and services.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Chf Solutions, Dia Imaging Analysis, Illuminoss Medical, Medtronic.
RSS
